5. Progressive supranuclear palsy Clinical trials / Disease details


Clinical trials : 89 Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03625128
(ClinicalTrials.gov)
January 2, 201812/7/201818F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNULLCompleted20 Years90 YearsAll36Early Phase 1Taiwan
2EUCTR2017-000094-36-SE
(EUCTR)
31/03/201730/01/2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Skåne University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Sweden
3NCT02605785
(ClinicalTrials.gov)
November 20153/11/2015A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyA Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: F-18 AV 1451Mayo ClinicNULLRecruiting35 YearsN/AAll332N/AUnited States